FDA Approves Nonstimulant Shire Drug for ADHD
Links shared publicly online about this topic
US FDA approves change in labelling of Shire's Vyvanse caps - International
pharmabiz.com — “Shire plc, the global specialty biopharmaceutical company, announced that the US Food and Drug Administration (FDA) approved a change to the prescribing information for its” View full resource at pharmabiz.com
Most Recently Shared on May 8, 2010 at 8:07 am By:
Peter H Brown Doctor and Psychologist
US FDA approves change in labelling of Shire's Vyvanse caps http://bit.ly/cty6gS #ADHD
Shire receives FDA approval of Daytrana for ADHD in adolescents
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include ” View full resource at news-medical.net
Most Recently Shared on July 7, 2010 at 5:40 am By:
Shire receives FDA approval of Daytrana for ADHD in adolescents: Shire plc, the global specialty biopharmaceutical... http://bit.ly/atTr4s
FDA Approves Shire's ADHD Drug as Adjunct to Stimulant Therapy
genengnews.com — “Nine-week trial showed benefits of adding Intuniv for suboptimally responsive patients.” View full resource at genengnews.com
Most Recently Shared on February 28, 2011 at 6:58 pm By:
Peter H Brown Doctor and Psychologist
FDA Approves Shire's ADHD Drug as Adjunct to Stimulant Therapy http://bit.ly/fO0JDO #ADHD
Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD i” View full resource at news-medical.net
Most Recently Shared on November 15, 2010 at 3:49 pm By:
Shire announces FDA approval of Vyvanse Capsules CII for ADHD in adolescents: Shire plc, the global specialty bi... http://bit.ly/a0SfMQ
Shire Announces FDA Approval of Once-Daily Intuniv (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17
drugs.com — “Intuniv (guanfacine) is used to treat Attention-Deficit/Hyperactivity Disorder in children and adolescents aged 6 to 17 years. Includes Intuniv side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on September 4, 2009 at 12:32 am By:
FDA Approves Intuniv (guanfacine) for the Treatment of ADHD in Children and Adolescents - http://bit.ly/EObbC
Shionogi Announces FDA Approval Of KAPVAY™ - The First And Only Therapy Approved For Use With Stimulant Medication For The Treatment Of ADHD
medicalnewstoday.com — “Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., announced the U.S. Food and Drug Administration approval of the non-stimulant medication KAPVAY™ (clonidine hydrochloride” View full resource at medicalnewstoday.com
Most Recently Shared on October 6, 2010 at 3:05 pm By:
MNT ADHD & ADD News Health News
Shionogi Announces FDA Approval Of KAPVAY™ - The First And Only Therapy Approved For Use With Stimulant Medicati... http://mnt.to/3KPx
Shionogi Announces FDA Approval of Kapvay - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD
drugs.com — “Kapvay (clonidine hydrochloride) is used to treat Attention Deficit Hyperactivity Disorder (ADHD). Includes Kapvay side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 4, 2010 at 11:57 pm By:
FDA Approves Kapvay for the Treatment of ADHD - http://bit.ly/9mCUK6
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
drugs.com — “Vyvanse (lisdexamfetamine) is used to treat ADHD. Includes Vyvanse side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 15, 2010 at 11:03 pm By:
Drugs and Devices OW OW Health
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents: ... http://bit.ly/c1yPph #drug
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
drugs.com — “Vyvanse (lisdexamfetamine) is used to treat ADHD. Includes Vyvanse side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on November 15, 2010 at 10:57 pm By:
FDA Approves Vyvanse (lisdexamfetamine dimesylate) for the Treatment of ADHD in Adolescents - http://bit.ly/9kNj6A
First ADHD Add-On Drug Approved | Psych Central News
psychcentral.com — “The U.S. Food and Drug Administration (FDA) has given the green light to the nonstimulant medication Kapvay (clonidine hydrochloride) as the first drug used to” View full resource at psychcentral.com
Most Recently Shared on October 7, 2010 at 2:36 pm By:
Peter H Brown Doctor and Psychologist
First ADHD Add-On Drug Approved http://bit.ly/caL9Ct #ADHD
FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents
drugs.com — “Daytrana (methylphenidate) is used for attention deficit hyperactivity disorder. Information from Drugs.com includes Daytrana side effects, interactions, indications” View full resource at drugs.com
Most Recently Shared on July 8, 2010 at 7:20 pm By:
FDA Approves Daytrana for the Treatment of ADHD in Adolescents - http://bit.ly/aZ1hIE
Vyvanse Approved for Adolescent ADHD - Drugs.com MedNews
drugs.com — “Vyvanse (lisdexamfetamine dimesylate) capsules have been approved by the U.S. Food and Drug Administration to treat attention deficit hyperactivity disorder (AD” View full resource at drugs.com
Most Recently Shared on November 15, 2010 at 6:11 pm By:
Drugs and Devices OW OW Health
Vyvanse Approved for Adolescent ADHD: MONDAY, Nov. 15 -- Vyvanse (lisdexamfetamine dimesylate) capsules ha... http://bit.ly/9roJY5 #drug
FDA approves guanfacine ER tablets to treat ADHD in children, teens - - Drug Topics
drugtopics.modernmedicine.com — “FDA approved the use of once-daily guanfacine (Intuniv, Shire) extended-release tablets as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder in children and adolescents aged 6 to 17 years as part of a total treatment program.” View full resource at drugtopics.modernmedicine.com
Most Recently Shared on March 2, 2011 at 7:52 pm By:
FDA approves guanfacine ER tablets to treat ADHD in children, teens: FDA approved the use of once-daily gu... http://bit.ly/hRwbtM #adhd
Medical News: FDA Extends ADHD Drug Indication - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA has approved the non-stimulant guanfacine (Intuniv) for the treatment of attention deficit hyperactivity disorder (ADHD) in combination with other therapies, including stimulants” View full resource at medpagetoday.com
Most Recently Shared on February 28, 2011 at 7:19 pm By:
FDA Extends ADHD Drug Indication http://bit.ly/eeMoee
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants For The Treatment Of ADHD
medicalnewstoday.com — “Shire plc, (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV® (gu” View full resource at medicalnewstoday.com
Most Recently Shared on March 1, 2011 at 8:33 pm By:
FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets For Use As Adjunctive Therapy To Stimulants F... http://bit.ly/ePyJtA #adhd
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Peter H Brown
Peter H Brown Clinical Psychologist. I'm also a Husband & Dad & wannabe techno-junkie
-
News-Medical.Net
Medical News from Around the World
-
Peter H Brown
Peter H Brown Clinical Psychologist. I'm also a Husband & Dad & wannabe techno-junkie
Advertisement
